Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 332-335

  Mangili, G ^a   Petrone, M ^a   Gentile, C ^a   De Marzi, P ^a   Vigano R ^a   Rabaiotti, E ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Palmar plantar erythrodysesthesia; Pegylated liposomal doxorubicin; Regional cooling; Skin toxicity

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOXORUBICIN; PACLITAXEL; PYRIDOXINE;

ADULT; AGED; ANKLE; ARTICLE; CONTROLLED STUDY; CRYOTHERAPY; FEMALE; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THERAPY EFFECT; WRIST;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; ERYTHEMA; FEMALE; FOOT DERMATOSES; GENITAL NEOPLASMS, FEMALE; HAND DERMATOSES; HUMANS; MIDDLE AGED; PARESTHESIA; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES;

EID: 38649104826     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.021     Document Type: Article

References (21)

1. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 3 (1997) 987-993
2. Gibbs D.D., Pyle L., Allen M., Vaughan M., Webb A., Johnston S.R., et al. A phase I dose-finding study of a combination of pegylated doxorubicin (Doxil), carboplatin, and paclitaxel in ovarian cancer. Br J Cancer 86 9 (2002) 1379-1384
3. Gordon A.N., Feagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
4. Gordon A.N., Granai C.O., Rose P.G., et al. Phase II study of liposomal doxirubicin in platinum and paclitaxel refractory ephitelial ovarian cancer. J Clin Oncol 18 (2000) 3093-4000
5. Kim R.J., Peterson G., Kulp B., et al. Skin Toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynaecologic cancer. Gynecol Oncol 97 (2005) 374-378
6. Lopez A.M., Wallace L., Dorr R.T., Koff M., Hersh E.M., and Alberts D.S. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol (1999) 303-306
7. Negore E., Insa A., and Sanmartin O. Antineoplastic therapy-induced palmar plantar erytrodysesthesia ("hand-foot") syndrome. Incidence, recognition and management. Am J Clin Dermatol 1 4 (2000) 225-234
8. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., and Scambia G. Pegyleted liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 18 7 (Jan 17 2007) 159-164
9. Fabian C.J., Molina R., Slavik M., Dahlberg S., and Stephens R. Pyridoxine therapy for palmar plantar erythrodysesthesias syndrome associated with continuous 5-fluorouracil infusion. Invest New Drugs 8 1 (Feb 1990) 57-63
10. Eng C., Mauer A.M., Fleming G.F., et al. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol 12 (2001) 1743-1747
11. Drake R.D., Lin W.M., King M., and ferrar D. Oral dexamethasone attenuates Doxil induced palmar-plantar erythrodysesthesia in patients with recurrent gynaecologic malignancies. Gynecol Oncol 94 (2004) 320-324
12. Molpus K.L., Anderson L.B., Craig C.L., et al. The effect of regional cooling on toxicities associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93 (2005) 513-516
13. Dvorak H.F., Nagy J.A., Dvorak J.T., et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133 (1998) 95-109
14. Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89 (2000) 1037-1047
15. Jacobi U., Waibler E., Schulze P., et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann Oncol 16 (2005) 1210-1211
16. Lademann, A. Martschick, U. Jacobi, H. Richter et al. Investigation of Doxorubicin on the skin: A spectroscopic study to understand the pathogenesis of PPE Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 5093.
17. Bhasin S., Sunita, Gupta D.K., et al. Chemotherapy-induced palmar plantar erythrodysesthesia. J Assoc Physicians India 53 (2005) 155-156
18. Rose P.G., Maxson J.H., Fusco N., et al. Liposomal Doxorubicin in ovarian, peritoneal and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82 (2001) 323-328
19. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., and Belison J. Phase 2 trial of liposomal doxorubicin (40 mg/m) in platinum/paclitaxel refractory ovarian and fallopoan tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78 (2000) 369--72
20. Ranson M.R., Carmichael J., O'Bryrne K., et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15 (1997) 3185-3191
21. Lyass O., Hubert A., and Gabizon A.A. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 7 10 (Oct 2001) 3040-3046